bioRxiv Science⌕ Search

Biology subjects

Harding, E. K.

Publications and source records attributed to Harding, E. K..

2 recordsLinked to original sources

Spinal cord Ca2+ imaging reveals glial-driven central sensitization in post-traumatic osteoarthritis

Central sensitization may be defined behaviourally, cellularly, or molecularly; yet these can all vary depending on the model and duration. Current electrophysiological approaches are time and labour intensive. Here, we developed a Ca2+ imaging and analysis pipeline (CuMIN) that implements semi-automated detection and analysis of cellular Ca2+ activity in rodent spinal cord slices, from which distinct signatures were defined for various acute and chronic pain models. Spinal cord slices from male mice were isolated after inducing pathological pain in a variety of well-established surgical or pharmacological approaches, incubated in a cell-permeant Ca2+ indicator, and imaged with epifluorescence microscopy. Intensity and temporal features of spontaneous and glutamate-evoked Ca2+ events were processed by linear discriminant analysis to map unique clusters of activity for each pain model. The resulting activity map of spinal dorsal horn activity is substantially different in the surgical model of chronic pain induced by post-traumatic osteoarthritis (PTOA), which lacks clear mechanistic evidence of central sensitization. Specifically, the PTOA Ca2+ activity signature overlapped with chemotherapy-induced neuropathy and neuropathic pain models, both of which are associated with gliosis-induced central sensitization. We confirmed gliosis in the PTOA model by immunostaining IBA1 and GFAP and observed analgesic effects of intrathecal carbenoxolone, Gap27, and minocycline that targeted glial activity. These findings validate CuMIN as a sensitive and specific approach for defining the basic cellular signatures of spinal central sensitization, with the utility of identifying potential therapeutic targets and serving as a translational platform for novel drug discovery across various acute and chronic pain models.

neuroscience↗

Connexin-36-expressing Gap Junctions in VTA GABA Neurons Sustain Opiate Dependence

Drug dependence is characterized by a switch in motivation wherein a positively reinforcing substance becomes negatively reinforcing. Ventral tegmental area (VTA) GABA neurons form a point of divergence between two double dissociable pathways responsible for these respective motivational states. Here we show that this switch from drug-naive to opiate-dependent and withdrawn (ODW) motivation is contingent upon the gap junction-forming protein, connexin-36 (Cx36), in VTA GABA neurons. Intra-VTA infusions of the Cx36 blocker, mefloquine, in ODW rats resulted in a reversion to a drug-naive motivational state and a loss of opiate withdrawal aversions. Consistent with these data, conditional knockout mice lacking Cx36 in GABA neurons (GAD65-Cre;Cx36fl(CFP)/fl(CFP)) were perpetually drug-naive and never experienced opiate withdrawal aversions. Further, viral-mediated rescue of Cx36 in VTA GABA neurons was sufficient to restore their susceptibility to ODW motivation. Our findings reveal a functional role for VTA gap junctions that has eluded prevailing circuit models of addiction. SignificanceThe motivation to seek drugs can vary depending on prior exposure. For instance, recreational and habitual drug use can stem from a desire to experience the pleasurable or relieving properties of the substance, respectively. Here we identify a subpopulation of midbrain neurons that dictate opiate-seeking motivation via expression of the gap junction protein, connexin-36. We show that connexin-36 expression increases upon opiate dependence and withdrawal. We then demonstrate that this is not merely a correlation, as pharmacological or genetic manipulations that interfere with connexin-36 function prevent the development of opiate dependence in rats and mice. Our results identify gap junctions as a critical node in the pathogenesis of opiate addiction, and a potential new target for substance use disorder pharmacotherapies.

neuroscience↗